Uric Acid Goal for Tophi
For patients with tophaceous gout, target serum uric acid below 5 mg/dL (300 µmol/L) until complete tophus dissolution is achieved, then maintain lifelong levels below 6 mg/dL (360 µmol/L). 1
Target Levels: A Two-Phase Approach
Phase 1: Active Tophus Dissolution
- Target: <5 mg/dL (300 µmol/L)
- This lower target facilitates faster crystal dissolution in patients with severe gout manifestations including tophi, chronic arthropathy, and frequent attacks 1
- Maintain this aggressive target until complete crystal dissolution and resolution of tophi occurs 1
Phase 2: Long-Term Maintenance
- Target: <6 mg/dL (360 µmol/L)
- Once tophi have resolved, the target can be relaxed to <6 mg/dL for lifelong maintenance 1, 2
- This level remains below the saturation point for monosodium urate crystal formation 3
Critical Caveats
Avoid prolonged extreme lowering: Do not maintain serum uric acid <3 mg/dL long-term, as some evidence suggests potential protective effects of uric acid against neurodegenerative diseases 1
Clinical Implementation
The 2016 EULAR guidelines provide the strongest evidence base for these targets, with Grade C recommendation and high agreement (mean 8.8±0.5) among expert panels 1. The 2014 multinational 3e initiative independently confirmed these targets, recommending serum urate preferably below 0.30 mmol/L (5 mg/dL) for tophi with Grade B recommendation 2.
Monitoring strategy: Check serum uric acid levels regularly during dose titration and maintain the <5 mg/dL target specifically for tophaceous disease until imaging or clinical examination confirms complete tophus resolution 1. The duration at the lower target varies by individual crystal burden—patients with larger or multiple tophi require longer treatment at <5 mg/dL before transitioning to the maintenance target.
This treat-to-target approach has demonstrated superior outcomes compared to symptom-based management, with evidence showing that achieving these targets reduces flare frequency and promotes tophus resolution 4.